| Trade Names: | |
| Synonyms: | |
| Status: | Approved (1995) |
| Entry Type: | Small molecule |
| Molecule Category: | Salt Prodrug |
| UNII: | G447S0T1VC |
| Parent Compound: | VALACYCLOVIR |
Structure
| InChI Key | ZCDDBUOENGJMLV-QRPNPIFTSA-N |
|---|---|
| Smile | |
| InChI |
|
Physicochemical Descriptors
| Property Name | Value |
|---|---|
| Molecular Formula | C13H21ClN6O4 |
| Molecular Weight | 360.8 |
| AlogP | -0.8 |
| Hydrogen Bond Acceptor | 9.0 |
| Hydrogen Bond Donor | 3.0 |
| Number of Rotational Bond | 7.0 |
| Polar Surface Area | 151.14 |
| Molecular species | NEUTRAL |
| Aromatic Rings | 2.0 |
| Heavy Atoms | 23.0 |
Pharmacology
| Action | Mechanism of Action | Reference |
|---|---|---|
| INHIBITOR | Human herpesvirus 1 DNA polymerase inhibitor | FDA |
| Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
|---|---|---|---|---|---|---|
|
Transporter
Electrochemical transporter
SLC superfamily of solute carriers
SLC21/SLCO family of organic anion transporting polypeptides
|
- | - | - | - | 69 |
Indications
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Cytomegalovirus Infections | 3 | D003586 | ClinicalTrials |
| Psychotic Disorders | 2 | D011618 | ClinicalTrials |
| Schizophrenia | 2 | D012559 | ClinicalTrials |
| Uveitis, Anterior | 2 | D014606 | ClinicalTrials |
| HIV Infections | 1 | D015658 | ClinicalTrials |
| Herpes Simplex | 1 | D006561 | ClinicalTrials |
Related Entries
Scaffolds
Adverse Reactions
System Organ Classification (SOC)
Cross References
| Resources | Reference |
|---|---|
| ChEBI | 9919 |
| ChEMBL | CHEMBL1201110 |
| EPA CompTox | DTXSID2044210 |
| FDA SRS | G447S0T1VC |
| Guide to Pharmacology | 4824 |
| KEGG | C07184 |
| PubChem | 135398741 |
| SureChEMBL | SCHEMBL40830 |
| ZINC | ZINC01530713 |
CONTENTS